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ABBREVATIONS 
SLE    Systemic Lupus Erythematosus 
ANA    Anti-Nuclear Anti-bodies 
EBV    Epstein Barr Virus 
HRCT   High Resolution Computed Tomography 
ILD    Interstitial Lung Disease 
PFT    Pulmonary Function Test 
SCLE    Sub-acute Cutaneous Lupus Erythematosus 
CXR    Chest X Ray 
CRP    C - reactive protein 
RF    Rheumatoid Factor 
ACL    Anti-cardiolipin anti-body 
IVIg    Intravenous Immunoglobulin 
APL    Anti Phospholipid 
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INTRODUCTION 
 
 Systemic Lupus Erythematosus is one of the major causes of morbidity 
for a decade of life and mortality.  SLE is a chronic auto immune disease 
characterized by microvascular Inflammation with the generation of auto 
antibodies that can affect almost any organ system. 
 Its presentation and course are highly variable SLE and pulmonary 
manifestations. 
 The majority of patients with SLE develop pleural or pulmonary 
disease. In the course of their illness, diagnosed clinically and or by images 
technique. The pleura are the most common thoracic localization of SLE.   
 Record studies with the use of imaging techniques like HRCT chest 
suggest that not only pleural diseases are common but airway disease 
lymphadenopathy and interstitial lung diseases are also common than 
previously thought. 
 HRCT will also be useful in permitting invasive procedures like lung 
biopsy and bronchodilator lavage to specific site of interest.  
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AIM OF THE STUDY 
 
 To study various pulmonary involvement in Systemic lupus 
erythematosus 
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REVIEW OF LITERATURE 
 SLE is an auto immune disease in where autoantibodies and immune 
complexes may destroy organs and tissue by binding to cells. 
 Auto antibodies can be present without clinical manifestations initially 
in early stages of the disease. 
 It most commonly occurs in females more than males.  It most 
commonly occurs in the women of child bearing age. 
 As far as race is concerned, it is more common in black women.  
Pathogenesis and Etiology 
 It is due to interactions between susceptibility genes and environmental 
factors results
4
. In immune responses, this will be abnormal and vary among 
different patients. 
 Those immune responses may include: 
4 
1. Innate immunity can be activated  by various DNA complexes and 
RNA of viral origin and other origins 
2. Threshold for abnormal activation pathway appear to be reduced.  
In adoptive immunity cells (T and B lymphocytes). 
3. Ineffective regulatory CD4 and CD8 T cells. 
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4. Reduced clearance of immune complexes and of atopic cells. 
5. Self antigens are exposed in surface blebs of apoptotic cells.  
6. Example – Nucleosomal DNA / Protein, RNA / protein.  In SM, RO 
and La, phospholipids.   
7. Thus self-antigen, autoantibodies and immune complex exists for 
longer periods of time, allowing inflammation and disease to 
develop. 
8. Immune cells activation is accompanied by increased secretion of 
cytokines. 
9. In the setting of chronic inflammation → Accumulation of growth 
factors and products of chronic oxidation contribute to irreversible 
tissue damage, including fibrosis sclerosis, in glomeruli, arteries, 
brain, lungs and other tissues. 
10. In effect of micro (mi) RNAs on gene transcription, as well as post 
transcriptional epigenetic modification of DNA, which is hypo 
methylated in SLE, also contribute to diseases susceptibilities.  
11. Female sex is permissive for SLE with evidence of hormone effects. 
Genes on the X chromosome and epigenetic differences between 
genders playing a role.   
12 
 
12. Women exposed to estrogen containing oral contraceptives or HRT 
have an increased risk of developing SLE. 
13. Klinefelter’s syndrome patients have a significantly increased risk 
for SLE. 
Environmental stimuli4 
1. UV light 
2. EBV 
3. Silica dust 
4. Smoking 
In SLE patients auto antibodies will be present for more than three 
years before the appearance of first clinical symptoms. 
13 
 
 
 
 
 
Pathology 
 Histopathological examination of the biopsies of the affected site like 
skin shows deposition of immune complexes at the dermal epidermal 
junction, basal keratinocytes injury and T cells, inflammatory cell on the DEJ 
and surrounding blood vessels and dermal layers. 
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Various autoantibodies in Systemic Lupus Erythematosus 
1. Antinuclear antibodies (98) – ANA – Antigen recognized is multiple 
nuclear. 
2. Anti-ds DNA(70) – Antigen recognized DNA (Double stranded)  
3. Anti RNP (40) – Antigen recognized – protein complexed to U1 RNA 
4. Anti SM (25) – protein complexed to 6 pieces of nuclear U1 RNA 
5. Anti RO (SS-A) (30) – Protein complexed to hY RNA, primarily 
60KDa and 52kDa. 
6. Anti LA (SS-B) (10) – 47 KDa protein complexed to hY RNA 
7. Antihistone (70) – Histones associated with DNA (in nucleosome, 
chromatin) 
8. Antiphospholipid (50) – Phospholipids, Beta 2 glycoprotein cofactor, 
prothrombin. 
9. Antierythrocyte (60) – Erythrocyte membrane.   
10. Antiplatelet (30) – Surface and altered cytoplasms antigens on 
platelets.  
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11. Antineuronal (includes anti-glutamate) receptors – Neuronal and 
lymphocyte surface antigens. 
12. Antiribosomal P (20)-Protein in ribosomes.   
Diagnosis: 
SLE diagnosis is based on typical clinical features and autoantibodies. 
• Malar rash:  
• Discoid rash:  
• Photosensitivity 
• Oral ulcers 
• Arthritis: non-erosive  
• Serositis: pleuritis or pericarditis  
• Renal disorder:  
• Neurologic disorder:  
• Hematologic disorder: 
• Immunologic disorder:  
• Antinuclear antibodies:  
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Any combination of greater than or equal to 4 of 11 criteria, well documented 
at any time during an individual’s history, makes it likely that the patient has 
SLE. 
Diagnostic criteria specificity 95% and sensitivity 75%.4 
ANAs are positive in 98% patients during course of the disease.4 
Positive for many autoantibodies in an individual without clinical 
manifestation should not be considered diagnostic for Systemic lupus 
erythematosus, although such persons are at greater risk to develop systemic 
lupus erythematosus. 
Clinical manifestations of SLE 
Systemic Manifestation 
 It can be in the form of fatigue, malaise, fever, and anorexia or weight 
loss. Severe systemic illness requiring corticosteroid therapy can occur with 
fever, prostration, weight loss, and anemia with or without other organ 
targeted manifestation 
Musculoskeletal manifestations 
 Most patients in SLE have 
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• Intermittent polyarthritis-varying from minimal to disabled 
severely, characterized by swelling of soft tissue and joint 
tenderness, usually involving in hands, wrists, and knees. It is 
usually non erosive polyarthritis
4
 
• Arthralgia, myalgia 
• Joint deformities can develop in hands and feet in about 10% of 
patients 
• Myopathy/Myositis- myositis with clinical muscle weakness, 
elevated creatine kinase levels, positive MRI scan, and necrosis 
of muscle and muscle inflammation on biopsy can be seen, 
although most patients have myalgia without frank myositis 
• Ischemic necrosis of bone- it should be considered particularly if 
there are no other manifestations of active SLE and pain 
persisting as monoarthritis usually involving, such as knee, 
shoulder, or hip. The prevalence of ischemic necrosis of bone is 
increasing due to use of systemic glucocorticoid in SLE 
• Muscle Weakness- it can occur as a result of glucocorticoid 
therapies most commonly and antimalarial therapies rarely. And 
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it can also occur in active disease per se it’s important to 
distinguish. 
Cutaneous manifestations: lupus dermatitis can be classified as follows 
• Discoid lupus erythematosus(DLE) 
• Systemic rash 
• Sub-acute cutaneous lupus erythematosus(SCLE) or other 
Discoid lesions are approximately circumscribed lesion with lightly elevated, 
scaly hyper pigmented erythematous rims and DE pigmented, thin centers in 
which all dermal layers are permanently destroyed. Lesions will be disfigured 
and especially located on head and neck areas. Treatment consists of topical 
glucocorticoid and systemic antimalarial 
Other manifestations as follows 
• Photosensitivity 
• Malar rash 
• Oral ulcers 
• Alopecia 
• Vasculitic rash 
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• Others (eg : urticarial, subacute cutaneous lupus) 
Most common cutaneous manifestation is photosensitive, slightly raised, 
erythematous, occasionally, on the face, head and neck region, over chest and 
extensor surface of arm. 
Renal manifestations: 
 Nephritis is most dangerous manifestation of systemic lupus 
erythematosus, particularly in first decade of onset of disease nephritis and 
infection form the major cause of death 
 Since most of the cases of nephritis are asymptomatic it is important to 
do urine analysis in all suspected cases of SLE 
Classification of lupus nephritis: 
1. Minimal mesangial lupus nephritis 
2. Mesangial proliferative lupus nephritis 
3. Focal lupus nephritis 
4. Diffuse lupus nephritis 
5. Membranous lupus nephritis 
6. Advanced sclerotic lupus nephritis 
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Renal biopsy is useful in planning current and future therapies. Patients with 
dangerous proliferative forms belonging to class 3 and 4 usually have 
microscopic hematuria and proteinuria (>500mg per 24 h); approximately 
one-half develop nephrotic syndrome, and hypertension. If diffuse nephritis 
not treated, almost all patients develop End Stage Renal Disease within first 
two years of diagnosis. Therefore aggressive immunosuppression is indicated 
usually systemic glucocorticoids and cytotoxic drugs, unless 90% of 
glomeruli have irreversible damage
26 
Blacks are more likely to develop ESRD than whites 
Neurologic manifestations:  
There are many CNS and peripheral nervous system involvement in SLE, in 
some patients these are major cause of morbidity and death.it is important 
diagnose whether manifestation due to SLE or another condition such as 
infection in immunosuppressed individuals 4 
 If symptoms related to SLE or vascular occlusive disease should be 
differentiated 
• Cognitive disorder-it is the most common finding of diffuse CNS lupus 
including difficulties in memory and reasoning. 
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• Mood disorder-Psychosis sometimes may be dominant manifestation; 
it must be differentiated from glucocorticoid induced psychiatric 
manifestation which usually occurs in first week of glucocorticoid 
therapy if daily doses of prednisolone more than 40 mg or equivalent 
• Headaches are also common 
• Seizures 
• Mono- and polyneuropathy 
• Stroke, TIA 
• Acute confusional state or movement disorder 
• Aseptic meningitis-as a complication of NSAIDS Therapy 
• Myelopathy- is not rare 
Hematologic manifestations: 
• Anemia-it is the most frequent hematological manifestation of SLE 
usually normocytic normochromic reflecting chronic illness, or due to 
RBC lysis can be fast in onset and more pronounced requiring high 
dose glucocorticoid
4
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• Leukopenia (<4000/µl) is also common and associated with 
lymphopenia, but not granulocytopenia 
• Lymphopenia (<1500/µl) 
• Thrombocytopenia (<100000/µl)-it may be recurring problem. If 
platelet count above 40000/µl an abnormal bleeding absent, therapy 
may not be required. High dose glucocorticoid is usually useful in first 
few episodes of low platelet counts 
• Lymphadenopathy 
• Splenomegaly 
• Hemolytic anemia- Recurring or prolonged hemolytic anemia 
,requiring high dose glucocorticoid should be treated with an additional 
strategy 
Vascular occlusions- 
The rate of occurrence of, TIA, strokes, and, Coronary artery disease is 
increased in SLE patients 
 SLE patient with antibodies to phospholipid (APL) are associated with 
hypercoagulability and acute thrombotic events 
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 Ischemia in the brain can be caused by focal occlusion (either non 
inflammatory or associated with vasculitis) or by embolization from carotid 
artery plaques or from fibrinous vegetation’s of Libman-Sacks endocarditis
4 
IT can affect vascular system as follows 
• Arterial thrombosis 
• Venous thrombosis 
• Accelerated atherosclerosis-characteristic associated with higher rate 
of progression for atherosclerosis include old age, systemic 
hypertension, hypercholestremia, dysfunctional proinflammatory high-
density lipoproteins, repeated high scores for disease activity, high 
cumulative doses of glucocorticoid, and high levels of homocysteine. 
Statins therapies reduce levels of LDL in SLE patients 
SLE patient with positive antiphospholipid antibody: 
If a patient with SLE who had history of repeated fetal losses 
associated with venous clotting or arterial clotting and at least 2 positive test 
for aPL have APS and should be managed with long term anticoagulation 
with 
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• INR of 2-2.5 is recommended for patients with history of one 
episode of venous clotting
4
 
• INR of 3-3.5 is recommended for patients with recurring clots or 
arterial clotting particularly4 
Gastrointestinal manifestations:-  
• Non-specific (nausea, mild pain, diarrhea) 
• Abnormal liver enzymes-increases in serum (AST and ALT) are seen 
mostly when SLE flare present. 
• Vasculitis- involving intestine may be severe manifestation; 
perforations of intestine, ischemia, bleeding, and sepsis are frequent 
complications 
• Autoimmune peritonitis- It can manifest as diffuse abdominal pain 
Aggressive immunosuppressive treatment with large dose glucocorticoids for 
short period control; evidence of recurrence is an indication for additional 
therapies 
Ocular manifestations: 
• Sicca syndrome-are common manifestation in SLE 
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• Conjunctivitis- usually non specific 
• Episcleritis 
• Vasculitis- involving retinal vessel and optic neuritis are serious 
manifestation; loss of vision can develop over days to weeks 
Cardiac manifestations: 
• Pericarditis- it is the most common cardiac manifestation; it usually 
relived corticosteroid therapy and infrequently leads to tamponade 
• Pericardial effusions 
• Myocarditis-it is proven to improve on glucocorticoid or other 
immunosuppressive therapies 
• Libman-Sacks endocarditis- most serious cardiac manifestation can 
lead to valvular insufficiencies 
• Coronary artery disease 
Along with steroids, other supportive therapy for heart failure, treatment for 
arrhythmia, and embolic events 
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Pulmonary manifestations: (4, 5,) 
Systemic lupus erythematosus, the entire pulmonary system is susceptible to 
injury. Any of pulmonary parts—airways, lung parenchyma, along with 
vasculature, pleura, or the respiratory musculature—may be separately or 
simultaneously affected.  
 The pulmonary manifestations are thought to be the result of an 
immune complex mediated injury 
Most common pulmonary manifestation of SLE is pleural involvement 
either in the form of pleuritis with or without pleural effusion
4 
Other manifestations are 
• Pulmonary infections 
• Airway diseases 
• Acute lupus pneumonitis 
• Pulmonary alveolar hemorrhage 
• Shrinking lung syndrome 
• Interstitial lung diseases 
• Fibrosis 
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• Pulmonary hypertension 
• Pulmonary embolism 
• Mediastinal lymphadenopathy 
• Organizing pneumonia 
Pleural involvement: 
  Pleuritic pain with or without effusion is the most common 
manifestation of SLE, occurring majority of SLE patients. Pleurisy and 
pleural effusion may be the presenting and sole manifestation of disease. 
They are usually recurrent and may accompany more severe complications 
such as acute lupus pneumonitis or nephritis. Clinical features: chest pain, 
dyspnea, cough and fever. The chest radiograph may be normal-Dry pleurisy, 
or may demonstrate small to moderate effusion may be bilateral or unilateral. 
When unilateral there is no predilection for either side
5 
Effusions are serous or serosanguineous and exudative in nature. A 
positive double stranded pleural fluid DNA titer is nonspecific as opposed to 
the serum test, since it is found in pleural fluid in effusion due to malignancy 
and tuberculosis. 
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The most useful measurement in pleural fluid is pleural fluid ANA 
titer. Levels greater than 1:160 are very suggestive of lupus pleuritis
14 
Histopathology of the pleural tissue shows infiltrated with cells, and, 
with repeated episodes, pleural fibrosis supervenes12. Occasionally, a 
vasculities of the pleural vessels is detected, and immune complex 
deposition has been reported 
Corticosteroid treatment is effective for relief of pleural pain, but time 
to resolution of the pleural effusion is variable and probably unaffected by 
this treatment. In the unusual case, recurrent lupus pleuritis may result in 
massive pleural fibrosis and lung entrapment, necessitating a pleural 
stripping procedure
5 
Differential diagnosis for pleuritis and pleural effusion includes 
infectious complications, thromboembolic disease, and Para pneumonic 
effusion, congestive heart failure, and effusion secondary to thromboembolic 
disease 
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Acute lupus pneumonitis: 
8 
Acute lupus pneumonitis is a clinical syndrome with an underlying 
histology of diffuse alveolar damage (DAD) bronchiolitis obliterans 
organizing pneumonia, NSIP, or a combination of these. It mimics acute 
infectious pneumonia and may be presenting manifestation of SLE in up to 
50 percent of cases. In those with an established with an established 
diagnosis, it also appears during a flare-up of other systemic manifestation of 
SLE particularly pleuritis, pericarditis, arthritis, and nephritis. It is reportedly 
most common in postpartum period. It recurs and can progress to ILD
9 
It is associated with variable degree of respiratory impairment 
accompanied by focal or diffuse pulmonary consolidation and often 
accompanied by pleural effusion and cardiomegaly due to underlying 
pericardial effusion or myocarditis, are present in chest X ray at presentation 
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Because of the difficulty in distinguishing acute lupus pneumonitis 
from an infectious pneumonia, a bronchoalveolar lavage and sometimes an 
open lung biopsy are indicated prior to instituting anti-inflammatory and 
immunosuppressive therapy 
Acute respiratory failure in acute lupus pneumonitis often requires 
assisted mechanical ventilation. The mortality due to this is high, with cause 
of death being either respiratory failure, another complication of SLE, or a 
superimposed infection
5 
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Diffuse alveolar hemorrhage:
 22, 23, 24, and 25 
 Diffuse alveolar hemorrhage, although rare may be presenting 
manifestation of SLE. In majority of cases it occurs in well documented cases 
of SLE  
 It can also present with symptoms reminiscent of an infectious 
pneumonia or acute lupus pneumonitis, and additional symptoms of 
hemoptysis raises the possibility of this diagnosis. Hemoptysis can be present 
in 90 percent of people during the course of diffuse alveolar hemorrhage 
 Routine work up shows a falling hematocrit, and in 60 to 90 percent of 
patients an active glomerulonephritis is invariably present. A progressive 
serosanguineous bronchoalveolar lavage may be the first clue to this 
diagnosis  
In CT chest it usually appears as both lung infiltrates ranging from 
minimal ground glass opacities to dense consolidation It can be diffuse or 
patchy1, 2 
Pathological changes that are reminiscent of both acute lupus 
pneumonitis and diffuse alveolar hemorrhage with or without pulmonary 
capillaritis are not unusual in a single biopsy specimen. The mortality rate is 
very high 
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Treatment once infection is ruled out is corticosteroid which is the 
main stay of treatment. IV methylprednisolone in the dose of 1 to 2 gram per 
day for 3 to 4 days followed by tapering should be considered. Concomitant 
oral or parenteral cyclophosphamide or azathioprine is commonly 
administered, given the incidence of lupus nephritis 
 
Pulmonary fibrosis 
It is due to chronic interstitial pulmonary disease. In more recent 
studies using HRCT many asymptomatic patients of SLE with normal chest x 
ray demonstrated pulmonary abnormalities consistent with some form of 
ILD. In those who develop ILD insidious onset of dyspnea are noted. The 
incidence of ILD in SLE is increasing in some of SLE patients with features 
suggestive of a mixed connective tissue disease 
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In patient who develop the slowly progressive form of ILD, the 
diagnosis of SLE is present for many years, and no other pattern of organ 
involvement predicts its appearance 
These patients have progressive dyspnea and cough with interstitial 
infiltration in chest radiograph 
In HRCT chest it appears as honeycombing changes with peripheral 
and basal predominance, linear thickened interlobular septae, ground glass 
attenuation and parenchymal bands 
PFTs reveal a restrictive pattern with reduction in the diffusion 
capacity and hypoxia accentuated by exercise. 
Responses to therapy either corticosteroid alone or in combination with 
cyclophosphamide or azathioprine, depends upon underlying histology. 
Those with underlying Nonspecific interstitial pneumonitis or organizing 
pneumonia are more likely to respond to treatment than those who 
demonstrate excess collagen deposition and cystic honeycomb formation 
34 
 
 
Lymphocytic interstitial pneumonia: 
In HRCT scan it may reveal ground glass opacity, poorly defined 
centrilobular nodular, thickening of bronchovascular bundle, interlobular 
septal and cystic airspaces 
Patchy alveolar infiltrates 
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Bronchiolitis  
Few patients of SLE are reported to have obstructive physiology. Obliterative 
bronchiolitis has been documented in SLE, but is rare in contrast to 
rheumatoid arthritis. Bronchiectasis may occur in up to 20 percent of patients 
but is often asymptomatic. Large airway involvement including tracheal and 
subglottic stenosis, vocal cord paralysis, epiglottitis, and necrotizing 
tracheitis have all been reported but are rare 
Pulmonary hypertension: 
Idiopathic pulmonary hypertension due to plexogenic arteriopathy is 
estimated to occur in 1 to 9 percent of patients. This form of patients 
associated with Raynaud phenomenon, digital vasculitis, and serositis, 
antibodies to ribonucleoprotein, rheumatoid factor, antiphospholipid 
antibodies, and most recently anti-endothelial antibodies. Patient complains 
of dyspnea and fatigue but have normal chest x ray. Few cases can result in 
right heart failure. In advanced cases, pulmonary arterial enlargement appears 
Spirometry and lung volumes are normal, but there is often an isolated 
reduction of the diffusing capacity for CO as well as gas exchange 
abnormalities. 
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Ventilation-perfusion lung scanning and, occasionally, pulmonary 
arteriography are indicated, particularly in those patient with 
antiphospholipid antibody syndrome who have a potential for recurrent small 
pulmonary emboli 
In HRCT chest dilated main pulmonary artery, abnormalities in 
perfusion, heterogeneity of lung attenuation
1, 2 
Therapeutic option include vasodilator therapy, anticoagulation, 
immunosuppression with cyclophosphamide, and transplantation 
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Pulmonary embolism: 
It is mostly associated with SLE with antiphospholipid syndrome. The 
most common epitope(s) to which antibodies exists in these patients is ß2-
glycoprotien I. A more appropriate term may therefore be anti-ß2-
glycoprotien syndrome. Up to a third of patients with SLE have 
antiphospholipid syndrome 
Chronic pulmonary embolism can lead to pulmonary hypertension 
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Pulmonary infections: 
It is usually due to SLE and secondary immunosuppression or as a 
result of complication of corticosteroid and immunosuppressant treatment. 
Any patient with SLE who presents with a febrile illness, cough with or 
without productive sputum, and new pulmonary infiltrates must be 
considered to have an infectious pneumonia, although acute lupus 
pneumonitis and diffuse alveolar hemorrhage may have similar presentation. 
Infectious pneumonia represents one of the most common causes of mortality 
in SLE. Bronchoalveolar lavage is often helpful in excluding an infectious 
pneumonia in the immunocompromised SLE patient5 
Mycobacterial and Nocardial infection seem particularly important 
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Shrinking lung syndrome: 
It is estimated that weakness of the diaphragm and other respiratory 
muscles is found in one fourth of SLE patients. This accounts for previously 
unexplained findings of dyspnea without any markers of interstitial lung 
disease or pulmonary vascular disease. These patients will have bibasilar 
atelectasis, an elevated diaphragm on chest x ray, and restrictive physiology. 
This has been called as shrinking lungs syndrome 
Although there is a reduction in a static lung volume, the diffusing 
capacity, when corrected for alveolar volume, remains normal, thereby 
distinguishing respiratory muscle dysfunction from interstitial lung disease. 
The likely explanation for this is a reduction in the Trans diaphragmatic 
pressure generated during maximal inspiration, which in turn reduces static 
lung compliance, producing the linear atelectasis seen on chest x ray. 
Moreover, in patients with respiratory muscle weakness no evidence for a 
generalized neuromuscular disease can be found. The pathogenesis of 
respiratory muscle dysfunction remains unexplained, although phrenic nerve 
conduction abnormalities have been excluded. 
Corticosteroids are not frequently effective treatment modality. CPAP 
or BiPAP, particularly at night, may improve these patients’ daytime 
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symptoms, although there is limited evidence available to support 
noninvasive nocturnal ventilation 
 
Acute Reversible Hypoxemia Syndrome 
28 
 It occurs in acutely ill SLE patients who are experiencing systemic 
exacerbation have been noticed. These patients have hypoxia and a increased 
A-a O2 gradient, but both the chest x ray and ventilation-perfusion lung scans 
are normal.it is postulated that there is complement-activated neutrophil 
aggregation in the pulmonary vasculature. The hypoxemia improves with 
immunosuppressive therapy 
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 Given the high incidence of antiphospholipid syndrome it is better to 
exclude thromboembolic manifestation before considering diagnosis of acute 
reversible hypoxia syndrome 
Investigation 
Tests for autoantibodies: 
ANA: Usually positive in 95% of patients 
Anti-dsDNA: increase in quantities of anti-dsDNA, indicates a severe 
manifestation of nephritis or Vasculitis especially if it is associated with 
decreasing level of C3 or C4 complements
4 
APL: APL identities patient at increased risk for venous clotting or arterial 
clotting, low platelet count and fetal loss
4 
Anti-Ro: it indicates increased risk for neonatal lupus syndrome, neonatal 
heart blocks sicca syndrome and sub-acute cutaneous lupus erythematosus 
Thus women of reproductive age group should be looked for anti-
phospholipid antibody and anti-Ro. 
Other standard tests for diagnosis: 
 Complete blood count 
 Platelet count 
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 Urine analysis 
These will help in detecting abnormalities that contribute to the diagnosis and 
influence management decisions. 
Tests for following disease course: 
 Anti-DNA antibodies level 
 Several components of complement 
 Activated complement products 
 Soluble IL-2 levels 
 IFN-inducible gene expression in peripheral blood cells 
 Neutrophil gelatinase associated lipocalin 
 Monocyte chemotactic protein-1 
 Urinary level of TNF-like weak inducer 
Treatment: 
SLE cannot be cured completely and sustained remissions are rare. 
Treatment given either in the basis of 
1. Conservative therapies for management non-life threatening 
SLE 
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2. Management of life-threatening SLE 
3. Special conditions in SLE that may require additional or 
different therapies 
4. Preventive therapies 
5. Experimental therapies 
Medications for management of SLE: 
NSAIDs and salicylates 
Dose range: higher dose usually required 
Drug interactions: Angiotensin II receptor blockers, ACEI, Steroids, 
antifungal (AZOLES), Methotrexate, Thiazides, 
 Adverse drug reactions: Increased chance of aseptic meningitis, Decreased 
renal function, Vasculitis of skin 
COX-2 specific inhibitors may aggravates coronary artery disease 
Aspirin can cause hearing damage and tinnitus 
NSAIDS and aspirin can cause gastrointestinal events and symptoms, allergic 
manifestations, dermatitis, giddiness, acute kidney injury, edema and SHT 
Glucocorticoids for topical application 
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Dose: mild dose for face, mild –high dose for other sites 
Drug interactions: no interaction 
Adverse drug reactions:  
Skin thinning, dermatitis of applied area, folliculitis, decreased pigmentation, 
skin infection 
Topical sunscreen 
Dose: SPF 15 at least (30+ advised) 
Drug interaction; no drug interaction 
Adverse drug reactions: 
Dermatitis on applied site 
Hydroxychloroquine 
Dose: 200-400 mg qd 
Drug interactions: none 
Adverse drug reactions: Retinal damage, agranulocytosis, aplastic anemia, 
ataxia, cardiomyopathy, Dizziness, Myopathy, Ototoxicity, Peripheral 
neuropathy, Pigmentation of skin, Seizures, Thrombocytopenia 
Dehydroepiandrosterone (DHEA) 
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Dose: 200 mg qd 
Drug interactions: unclear 
Adverse drug reactions: acne, menstrual irregularities, increased levels of 
androsterone 
Methotrexate 
Usually used for skin manifestation and joint manifestation 
Dose: 10-25 mg once a week with folic acid, reduce dose in renal patients 
according to GFR 
Drug interactions: Retinoid, Leflunomide, aspirin, Beta lactams, 
Sulphonamides, Trimethoprim, 
 Adverse drug reactions: reduced hemoglobin, BM suppression, Leukopenia, 
low platelet count, liver and renal effects, Infections, CNS toxicity, 
pulmonary effects, Pneumonitis, Severe skin manifestation, fits 
Teratogenicity – pregnancy category X 
Glucocorticoids and methylprednisolone 
Dose: Prednisolone: 50mg/d for 50 kg individual for SLE flare, 5to 15mg/d 
for milder disease 
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Methylprednisolone: 1 g IV qd for 3 days for severe disease 
Drug interactions: Angiotensin II receptor blockers, ACE inhibitors, 
Antiarrhythmic, pain killers, Non-steroidal anti-inflammatory other 
immunosuppressant Phenytoin, diuretic (acting on DCT), OHA, coumarins 
derivatives 
Adverse drug reactions: Infections, Zoster infection, Hypertension, High 
sugar, low serum potassium, Acne, Allergic manifestation, Anxiety, ischemic 
necrosis of bone, Cushingoid feature, Congestive heart failure, thin skin, 
decreased sleep, Menstrual , irregularity, Mood variability, reduced bone 
density, Psychiatric manifestations 
 
Cyclophosphamide 
Dose: 7-25 mg/kg/month for 6 months, followed by maintenance with daily 
oral mycophenolate or azathioprine 
Drug interactions: With drug used to treat hyperuricemia, BM suppressants, 
G-CSF, Hydroxydaunorubicin, Anti CD20, SCH, 
Adverse drug reactions: Zoster infection, BM suppression, painless 
hematuria, CA bladder, decreased hair, vomiting, loose stools, Myalgia, 
Neoplasia,  
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Ovarian dysfunction and testicular dysfunction 
Can be reduced by treatment with gonadotropin releasing hormone agonist 
(Lupron 3.75 mg IM) prior to monthly cyclophosphamide dose 
Teratogenicity – pregnancy category D 
Mycophenolate mofetil 
Dose: 2-3 g/d 
Drug interactions: antiviral, Pro-drug for mercaptourine, cholestyramine, 
ferrous salts, OCP 
Adverse drug reactions: Infection, Bone marrow suppression, 
Lymphoproliferative disorder, neoplasia, hair loss, loose stools, pyrexia, 
Headache, High blood pressure, dyslipidemia, low serum potassium, 
decreased sleep, bilateral leg swelling, involuntary movements of peripheral 
joints, macular Rash 
Azathioprine:  
Dose: 100to 150mg/d, reduction of dose if increased renal parameter 
Drug interactions: Many drugs should be careful 
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Adverse drug reactions: infection, zoster infection, BM suppression, liver 
toxicity, neoplasia, hair loss, pyrexia, flu like manifestation gastrointestinal 
symptoms, teratogenicity – pregnancy category D 
Belimumab: 
Dose: 10 mg/kg IV 
Drug interactions: IVIg 
Adverse drug reactions: infusion reactions, infections 
Rituximab: 
Dose: 375 mg/m
2
 once a week for 4 weeks 
Drug interactions: IVIg 
Adverse drug reactions: PML infection, infusion reaction, headache, 
arrhythmias, allergic responses, teratogenicity – pregnancy category C 
Preventive therapies:
 4 
• Appropriate vaccination: administration of influenza vaccine and 
pneumococcal vaccine 
• preventing frequent UTIs 
• Steps to be taken to prevent osteoporosis 
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• Treatment of hypertension and appropriate  steps to prevent 
development of atherosclerosis including control of dyslipidemia, 
treatment of hyperglycemia, management of obesity 
Experimental therapies:
4 
• Activated B lymphocytes with anti-BLyS or TACI-Ig 
• Inhibition of IFN-α 
• Inhibition of B/T cell second signal co-activation with CTLA-Ig 
• Inhibition of innate immunity activation via TLR7 or TLR9 and 
induction of regulatory T cells with peptides from immunoglobulin’s 
or auto antigens 
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MATERIAL AND METHODS 
Rheumatology Ward, Outpatient of Medical and Rheumatology O.P. of Rajiv 
Gandhi Government General Hospital during period from May 2012 to 
October  Systemic Lupus Erythematosus patient admitted in Medical 
Ward, 2012, were selected for this study. 
INCLUSION CRITERIA 
Patient known case of SLE fulfilling ACR Criteria with disease 
duration more than 5 years were taken into the study.  
EXCLUSION CRITERIA 
• Childhood Lupus 
• Pregnancy  
• Overlap Syndrome 
• Mixed Connective Tissue Disorder 
• ILD due to occupational lung Disease and other Non-lupus causes. 
Detailed history was taken from patient according to questionnaire and 
subjected to thorough clinical examination and Investigations. And even 
history regarding presence or absence of Lupus Nephritis was taken. 
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SAMPLE SIZE: 
50 Patients  
STUDY DESIGN: 
Cross sectional study 
STUDY POPULATION 
SLE patient attending medicine and rheumatology op and admitted in 
medical and rheumatology ward 
STUDY CENTRE 
Madras Medical College and Rajiv Gandhi Government General Hospital, 
Chennai 
METHODOLOGY 
 Patients with SLE more than 5 years disease duration were taken into 
the study. Both symptomatic and asymptomatic have been taken into study 
Respiratory symptoms: 
Cough with or without expectoration 
Dyspnea 
52 
 
Hemoptysis 
Pleurisy  
Patient were subjected to thorough history and physical examination  
Patients were subjected to the following investigation 
Chest X-ray,  
HRCT Chest, 
Pulmonary function tests, 
Complete haemogram, 
Renal and liver function tests, 
Sputum analysis, 
Urine analysis  
Immunological investigations on need for basis are done such as 
 CRP  
 ANA 
 RF 
 Anti-ds-DNA 
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 ACL (IgM) and (IgG) 
 Cardiac evaluation is done by ECG and Echocardiography, Lupus 
Nephritis patient renal biopsy proven with Respiratory symptoms is also 
included. 
  And various finding like with pleuritis with or without pleural effusion, 
alveolitis, interstitial fibrosis, lupus pneumonitis, shrinking lung syndrome, 
Intra – alveolar Hemorrhage, pulmonary thromboembolism 
 And pulmonary arterial Hypertension, secondary effects are atelectasis, due 
to diaphragmatic weakness, pneumonia, drug side effects and pleura-
pulmonary consequences of cardiac failure and renal failure.  
Ethical Committee Clearance: 
 Obtained 
Informed Consent 
 Obtained from all patient included in study 
Statistical Analysis 
 Statistical analysis done using SPSS software 
Conflict Of Interest None 
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OBSERVATION AND RESULTS 
AGE DISTRIBUTION 
AGE(in 
years) 
MALE FEMALE TOTAL PERCENTAGE 
20 to 25  3 3 6 
26 to 30 2 4 6 12 
31 to 35 2 10 12 24 
36 to 40  14 14 28 
41 to 45  3 3 6 
46 to 50  8 8 16 
51 to 55  4 4 8 
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SEX DISTRIBUTION 
SEX NO.OF PATIENTS PERCENTAGE 
MALE 4 8 
FEMALE 46 92 
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DURATION DISTRIBUTION 
DURATION(in years) NO.OF PATIENTS PERCENTAGE 
5-10 19 38 
11-15 15 30 
16-20 5 10 
21-25 9 18 
26-30 2 4 
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SYMPTOMATIC AND ASYMPTOMATIC DISTRIBUTION 
MANIFESTATION NO. OF PATIENTS PERCENTAGE 
SYMPTOMATIC 22 44 
ASYMPTOMATIC 28 56 
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SYMPTOMS DISTRIBUTION 
SYMPTOMS NO.OF PATIENTS PERCENTAGE 
COUGH 4 8 
COUGH WITH 
EXPECTORATION  
2 4 
DYSPNEA 8 16 
PLEURISY 12 24 
ASYMPTOMATIC 28 56 
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DISEASE DISRIBUTION 
DISEASES NO.0F PATIENTS PERCENTAGE 
PLEURITIS WITH 
EFFUSION 
12 24 
CONSOLIDATION 
WITH EFFUSION 
2 4 
ASYMPTOMATIC 
PLEURAL EFFUSION 
2 4 
SYMPTOMATIC ILD 3 6 
ASYMPTOMATIC ILD 10 20 
PNEUMONITIS 3 6 
ASYMPTOMATIC 
MEDIASTINAL 
LYMPHADENOPATHY 
2 4 
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PLEURISY DISTRIBUTION 
PLEURISY NO.OF PATIENTS PERCENTAGE 
PLEURITIS 12 24 
CONSOLIDATION 
WITH EFFUSION 
2 4 
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DYSPNEA DISTRIBUTION 
DYSPNEA NO. OF PATIENTS PERCENTAGE 
ILD 6 12 
OTHER CAUSES 2 4 
 
 
 
 
 
 
 
 
 
 
ILD OTHER CAUSES
62 
 
LUPUS NEPHRITIS DISTRIBUTION 
LUPUS NEPHRITIS NO.OF PATIENT PERCENTAGE 
PRESENT 6 12 
ABSENT 44 88 
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LUPUS NEPHRITIS AND PULMONARY MANIFESTATION 
LUPUS NEPHRITIS NO.OF PATIENTS PERCENTAGE 
CONSOLIDATION 
WITH EFFUSION 
1 16.6 
PLEURAL 
EFFUSION 
2 33.3 
NO 
MANIFESTATION 
3 50 
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PLEURAL EFFUSION
NO MANIFESTATION
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X RAY AND NO OF POSITIVE CASES 
X RAY FINDING NO.OF PATIENTS PERCENTAGE 
PRESENT 13 26 
ABSENT 37 74 
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X RAY AND ITS FINDINGS 
X RAY FINDINGS NO.OF PATIENTS PERCENTAGE 
 PLEURAL 
EFFUSION 
8 61.54 
RETICULAR 
OPACITY 
3 23.07 
CONSOLDATION 
WITH EFFUSION 
2 15.38 
 
 
 
 
 
 
 
0
1
2
3
4
5
6
7
8
PLEURAL EFFUSION RETICULAR
OPACITY
CONSOLIDATION
EFFUSION
NO.OF PATIENTS
NO.OF PATIENTS
66 
 
HRCT DISTRIBUTION AMONG SYMPTOMATIC AND 
ASYMPTOMATIC 
MANIFESTATION HRCT  PERCENTAGE 
SYMPTOMATIC  20 40 
ASYMPTOMATIC 14 28 
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HRCT AND VARIOUS MANIFESTATIONS 
HRCT NO.OF PATIENTS PERCENTAGE 
PLEURITIS WITH 
EFFUSION 
14 41.17 
ILD 13 38.23 
CONSOLIDATION 
WITH EFFUSION 
2 5.88 
MEDIASTINAL 
LYMPHADENOPATHY 
2 5.88 
PNEUMONITIS 3 8.82 
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HRCT AND ITS FINDINGS 
HRCT FINDING NO.OF PATIENTS PERCENTAGE 
PLEURAL EFFUSION 14 41.17 
CONSOLIDATION 
WITH EFFUSION 
2 5.88 
INTERSTITIAL 
THICKENING 
13 38.23 
GROUND GLASS 
OPACITY 
11 32.35 
PARENCHYMAL 
BANDS 
2 5.88 
MEDIASTINAL 
LYMADENOPATHY 
2 5.88 
 
 
 
 
 
 
0 2 4 6 8 10 12 14
PLEURAL EFFUSION
CONSOLIDATION WITH EFFUSION
INTERSTITIAL THICKENING
GROUND GLASS OPACITY
PARENCHYMAL BANDS
MEDIASTINAL LYMADENOPATHY
PNEUMONITIS
NO.OF PATIENTS
NO.OF PATIENTS
69 
 
PULMONARY FUNCTION TEST 
PFT FINDINGS NO.OF PATIENTS PERCENTAGE 
RESTRICTIVE 
PATTERN 
7 14 
OBSTRUCTIVE 
PATTERN 
0 0 
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HRCT AND X RAY COMPARISON 
IMAGE NO.OF PATIENTS PERCENTAGE 
HRCT CHEST 
ALONE POSITIVE 
21 42 
X RAY CHEST AND 
HRCT CHEST 
POSITIVE 
13 26 
BOTH HRCT CHEST 
AND X RAY CHEST 
NEGATIVE 
16 32 
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HRCT AND PFT COMPARISON 
INVESTIGATION NO.OF PATIENTS PERCENTAGE 
HRCT CHEST 
ALONE POSITIVE 
27 54 
HRCT CHEST AND 
PFT POSITIVE 
7 14 
HRCT CHEST AND 
PFT NEGATIVE  
16 32 
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SPUTUM RESULT DISTRIBUTION 
RESULT SPUTUM 
GRAM STAIN 
SPUTUM 
C/S 
PERCENTAGE 
POSITIVE 2 2 4 
NEGATIVE 4 4 8 
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DISEASE DISTRIBUTION ACCORDING TO SEX 
DISEASES MALE FEMALE TOTAL 
PLEURAL 
EFFUSION 
2 12 14 
CONSOLIDATION 
WITH EFFUSION 
1 1 2 
PNEUMONITIS 1 2 3 
ILD 0 13 13 
MEDIASTINAL 
LYMADENOPATHY 
0 2 2 
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ILD DISTRIBUTION IN RELATION TO DURATION 
DURATION IN 
YEARS 
NO.OF PATIENTS PERCENTAGE 
11-15 2 4 
16-20 1 2 
21 AND ABOVE 10 20 
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RESULTS 
 In the present study 50 SLE patients were taken into study group 
Age distribution 
 The present study observed that 70 per cent of patients of SLE were in 
3rd and 4th decade of life, 22 per cent of patients were in 5th decade of life and 
above 
Sex distribution 
 In our study sex distribution were 92 per cent of female and 8 per cent 
of male 
Duration distribution  
 The duration distribution of the present study were as follows 38 per 
cent of patients were between 5 to 10 years of duration, 30 per cent of 
patients were between 11 to 15 years of duration, 10 per cent of patient were 
between 16 to 20 years of duration, 18 per cent of patients were between 21 
to 25 years of duration, and 4 per cent of patients were between 26 to 30 
years of duration. 
 
 
76 
 
Symptomatic Vs. Asymptomatic  
 In our study among 50 patients, symptomatic were 22 patients (44%), 
and asymptomatic were 28 patients (56%) 
Symptoms distribution 
 In the present study cough was present in 8 per cent of patients, cough 
with expectoration was present in 4 per cent of patient, dyspnea was present 
in 16 per cent of patients, pleurisy was present in 24 per cent of patients, and 
32 per cent of patients were asymptomatic. 
Disease distribution 
 In our study various pulmonary manifestation were distributed as 
follows, pleuritis with effusion were present in 12 patients(24%), 
consolidation with effusion were present in 2 patients(4%), asymptomatic 
pleural effusion were present in 2 patients(4%), symptomatic interstitial lung 
disease was seen in 3 patients(6%), asymptomatic interstitial lung disease 
was seen in 10 patients(20%), pneumonitis were present in 3 patients(6%), 
and asymptomatic mediastinal lymphadenopathy in 2patients(4%). 
Pleurisy distribution 
 In the present study pleurisy was present in 12 patients of pleuritis and 
2 patients of consolidation with pleural effusion. 
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Dyspnea distribution 
 In our study total patients presenting with dyspnea were 8 patients, due 
to interstitial lung disease 6 patients, and in 2 patients due to other causes like 
anemia, nephritis and others 
Lupus nephritis distribution 
 In this study lupus nephritis was present in 6 patients (12%), and 
absent in 44 patients (88%). 
Lupus nephritis and pulmonary manifestation 
 In the present study out of 6 patients who had lupus nephritis, 
pulmonary manifestations are consolidation with effusion in 1 patient 
(16.6%), pleural effusion in 2 patients (33.3%), and 3 patients (50%) were no 
pulmonary manifestation. 
X ray distribution  
 In our study x ray findings were present in 26 per cent of patients (13), 
and normal x ray was seen in 74 per cent of patients (37). 
X ray and its findings 
 In present study positive x ray findings were seen in 13 patients and 
various findings seen are as follows pleural effusion in 8 patients (61.54%), 
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reticular opacity in 3 patients (23.07%), and consolidation with effusion in 2 
patients (15.38%). 
HRCT chest distribution 
 In this study HRCT showed positive results in 20 patients who were 
symptomatic (40%), and among asymptomatic 14 patients had positive 
HRCT findings (28%), and rest of 16 patients who were asymptomatic 
showed normal HRCT. 
HRCT chest and various pulmonary manifestations 
 In our study among 34 patients who had HRCT findings various 
pulmonary manifestation seen are as follows, pleuritis with pleural effusion 
was seen in 14 patients (41.17%), interstitial lung disease was present in 13 
patients (38.23%), pneumonitis was seen in 3 patients (8.82%), consolidation 
with effusion in 2 patients (5.88), and mediastinal lymphadenopathy in 2 
patients (5.88). 
HRCT and its findings 
 In the present study various HRCT findings found are pleural effusion 
was present in 14 patients (41.17%), consolidation with effusion in 2 patients 
(5.88), interstitial thickening in 13 patients(38.23%), ground glass opacity in 
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11 patients (32.35%), parenchymal bands in 2 patients (5.88%), and 
mediastinal lymphadenopathy in 2 patients (5.88%). 
Pulmonary function test results 
 In our study pulmonary function test was positive in 7 patients (14%), 
all of which were restrictive patterns and no case of obstructive pattern seen 
in pulmonary function test. 
HRCT and x ray comparison 
 In this study HRCT alone were positive in 21 patients (42%), x ray 
chest and HRCT both positive in 13 patients (26%), and both HRCT and x 
ray chest negative in 16 patients (32%). 
HRCT and pulmonary function test comparison 
 In this study HRCT alone positive in 27 patients (54%), both HRCT 
and PFT positive in 7 patients (14%), and both HRCT and PFT negative in 16 
patients (32%). 
Sputum result distribution 
 In the present study cough was present in 6 patients, sputum test done 
for these patient such as sputum gram stain was positive in 2 patients 
(33.3%), and negative in 4 patients (66.6%), and sputum culture was positive 
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in 2 patients and negative in 4 patients. Both sputum gram stain and culture 
positive were of same patients. 
Disease distribution according to sex 
 In our study male patients with pulmonary manifestations are pleural 
effusions in 2 patients, pneumonitis in 1 patient, and consolidation with 
effusion in 1 patient. Among females pleural effusions was present in 12 
patients, consolidation with effusion in 1 patient, pneumonitis in 2 patients 
interstitial lung disease in 13 patients and mediastinal lymphadenopathy in 2 
patients. 
Interstitial lung disease distribution in relation to duration 
 In the present study ILD in respect to duration are as follows, in 11 to 
15 years of duration of disease 2 patients had ILD, between 16 to 20 years 1 
patient had ILD, and duration of 21 years and above ILD present in 10 
patients 
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 DISCUSSION 
The present study was conducted in 50 cases of SLE to study the various 
pattern of pulmonary involvement and to render help in the management of 
the problem detected out of them. All patients were subjected to routine 
clinical examination and specific investigations. 
Age Distribution 
In this series of 50 patients of SLE, the age of patient ranged from 20 
to 55 years with maximum incidence in 3
rd
 and 4
th
 decade of life. In study 
conducted by S Kakati et al, total 40 patients of SLE were included, the age 
of the patients ranged from 12 to 60 years with maximum incidence between 
16 to 25 years
1
. In study by H M Fenlon et al total numbers of SLE patients 
were 34 patients, patient’s age group ranging from 15 to 68 years
2
. 
Sex Distribution 
 In our study total numbers of female patients were 46(92%), and male 
patients were 4 (8%). In study by S Kakati et al total numbers of female 
patients were 37(93.11%), and male patients were 3(7.89%)1. In study by  
H M Fenlon et al total numbers of female patients were 32(94%), 2 males 
(6%)
 2
. 
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Duration Distribution 
 In our study mean interval since the diagnosis of study was16 years.  
H M Fenlon et al study mean duration since SLE was diagnosed were 5 years 
Symptomatic and Asymptomatic Distribution 
 In the present study 22 patients (44%), were symptomatic and 28 
patients were asymptomatic (56%). 
In study by S Kakati et al out of 40 patients 9 were symptomatic (23.68%), 
and 31 patients were asymptomatic (77.5%)
1. 
In study by H M Fenlon et al 26 patients (77%) were asymptomatic and 8 
patients (23%) were symptomatic
2
. 
In study by Donato Alarcon Segovia et al out of 48 patients 21 patients (44%) 
were symptomatic and 27 patients were asymptomatic
3
. 
Symptom Distribution 
 In the present study pleurisy was seen in 12 patients, dyspnea in 8 
patients, cough in 4 patients and cough with expectoration in 2 patients. 
In study by S Kakati et al out of 40 patients 6 had cough, 4 had dyspnea and 3 
had pleurisy
1
. 
83 
 
In study by Fenlon et al 6 patients had dyspnea, 1 had wheeze and 1 had 
pleurisy
2
. 
In study by Donato Alarcon Segovia cough was present in 21 patients, 
dyspnea in 18 patients, cough with expectoration in 14 patients, pleurisy in 
12 patients and hemoptysis in 5 patients. 
Disease Distribution 
 In our study pleuritis with effusion were present in 14 patients (28%), 
consolidation with effusion in 2 patients (4%), ILD in 13 patients (26%), 
pneumonitis in 3 patients (6%) and lymphadenopathy in 2 patients (4%). 
In study by S Kakati et al pleural effusion in 4 patients(10.53%), ILD in 15 
patients(39.47%), consolidation in 2 patients(5.26%), lymphadenopathy in 2 
patients(5.26%) and bronchiectasis in 3 patients(7.8%)
1
. 
In study by Fenlon et al 11 patients(33%) had ILD, pleural effusion in 7 
patients(21%), lymphadenopathy in 6 patients(18%), bronchiectasis in 7 
patients(21%) and consolidation in 2 patients(6%)2. 
Lupus Nephritis Distribution 
 In our study lupus nephritis was present in 6 patients (12%) and absent 
in 44 patients (88%).IN S Kakati et al study lupus nephritis was present in 23 
patients (69%) 
1
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X ray, HRCT and Pulmonary Function Test Results Distribution 
 In our study X ray finding were present in 13 patients (26%). HRCT 
findings were present in 34 patients (68%). PFT was restrictive pattern in 7 
patients (14%) and obstructive pattern in none. 
In study S Kakati et al X ray findings were positive in 7 patients (18.42%). 
PFT had abnormality in 11 patients (28.95%). 10 had restrictive pattern 
(26.32%) and 1 had obstructive pattern (2.63%)
1
. HRCT findings were 
present in 21 patient s (55.26%).
1
 
In study by Fenlon et al X ray finding were present in 8 patients(24%).HRCT 
was abnormal in 24 patients(70%).PFT had abnormality in 9 patients of 
which 6 had restrictive pattern and 3 had obstructive pattern.
2 
Symptomatic and Asymptomatic Disease Distribution in X ray, HRCT 
and PFT 
 In our study HRCT was abnormal in 34 patients (68%) out of which 20 
were symptomatic and 14 were asymptomatic. Chest X ray was abnormal in 
13 patients and all were symptomatic. PFT was abnormal in 7 patients out of 
which 3 patients were symptomatic and 4 were asymptomatic. 
In S Kakati et al study 21 patients had abnormal HRCT findings (55.26%) 
out of which 9 were symptomatic and 12 were asymptomatic. Chest X ray 
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was abnormal in 7 patients who were symptomatic. PFT was abnormal in 11 
patients out of which 7 were symptomatic and 4 were asymptomatic
1
. 
In study by Fenlon et al 24 patients had abnormal HRCT findings (70%) out 
of which 8 were symptomatic and 16 were asymptomatic. Chest X ray was 
abnormal in 8 patients and all were symptomatic. PFT was abnormal in 9 
patients out of which 8 were symptomatic and 1 was asymptomatic.
2
 
HRCT Findings 
 In our study pleural effusion was seen in 14 patients, consolidation 
with effusion in 2 patients, interstitial thickening in 13 patients, ground glass 
opacity in 11 patients, parenchymal bands in 2 patients and lymphadenopathy 
in 2 patients. 
In S Kakati et al study pleural effusion was seen in 4 patients, thickened 
pleura in 1 patient, sub pleural band in 2 patients, lymphadenopathy in 2 
patients, interstitial thickening in 15 patients, ground glass opacity in 10 
patients, air space consolidation in 2 patients and bronchiectasis in 3 
patients.
1
 
In Fenlon et al study interstitial thickening in 15 patients, parenchymal bands 
in 15 patients, sub pleural bands in 7 patients, pleural effusion and thickening 
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in 7 patients, lymphadenopathy in 6 patients and ground glass opacity in 2 
patients.
2
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LIMITATIONS 
 The number of male patients taken up for study was low 
 Results need to be confirmed in a larger group of patients and 
longitudinal groups. 
 DLCO was not used to assess pulmonary function. 
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CONCLUSION 
1) SLE and pulmonary manifestation is a common manifestation and it is 
not a rare manifestation 
2) Pleural effusion with or without pleuritis and interstitial lung disease 
were of almost equal incidence still pleural effusion was slightly more 
common 
3) Even in asymptomatic patient with normal chest x ray and pulmonary 
function, HRCT chest detected pulmonary involvement in significant 
number of cases 
4) Thus it is important to do HRCT chest even with subtle clinical 
respiratory symptoms to detect early respiratory involvement and 
aggressively treat the respiratory manifestation without allowing it to 
develop into irreversible changes 
5) To concentrate also on pulmonary manifestation of SLE like that of 
lupus nephritis and not to tapper the immunosuppressive agent dose 
just by monitoring nephritis but also by monitoring pulmonary 
manifestation 
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PROFORMA 
STUDY OF PULMONARY MANIFESTATIONS IN SYSTEMIC LUPUS 
ERYTHEMATOSUS 
Name : 
Age/Sex : 
IP No : 
Patient ID : 
 
Symptoms Co-morbidities 
☐ Breathlessness ☐ Allergy 
☐ Cough ☐ Asthma 
☐ Expectoration ☐ Tuberculosis 
☐ Hemoptysis ☐ COPD 
☐ Pleuritic chest pain ☐ Non-lupus ILD 
 
Examination Respiratory system 
☐ Pallor Chest expansion: cm 
☐ Icterus ☐ Chest symmetric 
☐ Cyanosis ☐ Crackles 
☐ Clubbing ☐ Wheeze 
☐ Lymphadenopathy ☐ Pleural rub 
☐ Pedal edema Others: 
 
Integuments Vitals 
Skin: Pulse: 
Hair: Blood pressure: 
Nails: Respiratory rate: 
 
Complete hemogram Liver function tests 
TC : Total bilirubin : 
DC : Direct bilirubin : 
ESR : AST : 
Hb : ALT : 
PCV : ALP : 
Platelets : Total protein : 
RBCs : Albumin : 
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Renal function tests Fasting lipid profile 
Glucose : Total cholesterol : 
Urea : HDL : 
Creatinine : LDL : 
Urinanalysis Triglycerides : 
☐ Albumin  
☐ Sugar  
Deposits :  
 
Sputum analysis 
 
Immunology 
 
RF : 
ANA : 
Anti-ds-DNA : 
C3 : 
C4 : 
ACL : [IgM] 
 : [IgG] 
LAC : 
 
Imaging 
Chest X-ray : 
 
USG chest : 
 
HRCT lung : 
 
Cardiac evaluation 
ECG : 
 
ECHO : 
 
Pulmonary function tests 
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MASTER CHART 
         CHEST X-RAY FINDINGS HRCT FINDINGS   
ID Age Sex Dyspnea Cough Hemoptysis Pleurisy Duration Nephritis 
XPleural 
Effusion 
XReticular 
Opacities 
XAtelec 
tasis 
XConso 
lidation 
CT Pleural 
Effusion 
CT Thickened 
Pleura 
CT Interstitial 
Thickening 
CT Bronchi 
ectasis 
CT Parenchymal 
Bands 
CT Ground 
Glass 
Opacities 
CT Consoli 
dation 
CT Lympha- 
denopathy 
PFT Sputum 
1 40 F Y N N N 12 N N Y N N N N Y N Y Y N N Restrictive - 
2 36 F Y Y N N 11 N N Y N N N N Y N Y Y N N Restrictive - 
3 35 M Y Y N N 15 N N N N N N N N N N Y N N Normal - 
4 40 F Y Y N N 15 N N N N N N N N N N Y N N Normal - 
5 46 F Y Y N N 16 N N N N N N N N N N Y N N Normal - 
6 51 F Y N N N 26 N N Y N N N N Y N N N N N Restrictive - 
7 25 M N Y N Y 6 Y Y N N Y Y N N N N N Y Y Normal + 
8 30 F N Y N Y 8 N Y N N N Y N N N N N Y Y Normal + 
9 30 F Y N N N 9 Y N N N N N N N N N N N N Normal - 
10 38 F Y N N N 11 N N N N N N N N N N N N N Normal - 
11 41 F N N N Y 14 N Y N N N Y N N N N N N N Normal - 
12 34 M N N N Y 7 N Y N N N Y N N N N N N N Normal - 
13 36 F N N N Y 8 N Y N N N Y N N N N N N N Normal - 
14 35 F N N N Y 12 N Y N N N Y N N N N N N N Normal - 
15 28 M N N N Y 10 N Y N N N Y N N N N N N N Normal - 
16 21 F N N N Y 6 N Y N N N Y N N N N N N N Normal - 
17 25 F N N N Y 7 N Y N N N Y N N N N N N N Normal - 
18 29 F N N N Y 7 N Y N N N Y N N N N N N N Normal - 
19 32 F N N N Y 10 N N N N N Y N N N N N N N Normal - 
20 33 F N N N Y 6 N N N N N Y N N N N N N N Normal - 
21 38 F N N N Y 8 N N N N N Y N N N N N N N Normal - 
22 39 F N N N Y 9 N N N N N Y N N N N N N N Normal - 
23 27 F N N N N 7 N N N N N N N N N N N N N Normal - 
         CHEST X-RAY FINDINGS HRCT FINDINGS   
ID Age Sex Dyspnea Cough Hemoptysis Pleurisy Duration Nephritis 
XPleural 
Effusion 
XReticular 
Opacities 
XAtelec 
tasis 
XConso 
lidation 
CT Pleural 
Effusion 
CT Thickened 
Pleura 
CT Interstitial 
Thickening 
CT Bronchi 
ectasis 
CT Parenchymal 
Bands 
CT Ground 
Glass 
Opacities 
CT Consoli 
dation 
CT Lympha- 
denopathy 
PFT Sputum 
24 40 F N N N N 12 N N N N N N N N N N N N N Normal - 
25 39 F N N N N 11 Y N N N N Y N N N N N N N Normal - 
26 28 F N N N N 8 Y N N N N Y N N N N N N N Normal - 
27 31 F N N N N 9 N N N N N N N N N N N N N Normal - 
28 48 F N N N N 21 N N N N N N N Y N N N N N Normal - 
29 48 F N N N N 24 N N N N N N N Y N N N N N Normal - 
30 45 F N N N N 22 N N N N N N N Y N N Y N N Normal - 
31 46 F N N N N 27 N N N N N N N Y N N Y N N Normal - 
32 54 F N N N N 25 N N N N N N N Y N Y Y N N Restrictive - 
33 49 F N N N N 23 N N N N N N N Y N Y Y N N Restrictive - 
34 50 F N N N N 25 N N N N N N N Y N Y Y N N Restrictive - 
35 51 F N N N N 24 N N N N N N N Y N N Y N N Restrictive - 
36 47 F N N N N 22 N N N N N N N Y N N N N N Normal - 
37 45 F N N N N 20 N N N N N N N Y N N N N N Normal - 
38 37 F N N N N 20 N N N N N N N N N N N N N Normal - 
39 39 F N N N N 19 N N N N N N N N N N N N N Normal - 
40 50 F N N N N 21 N N N N N N N N N N N N Y Normal - 
41 51 F N N N N 19 N N N N N N N N N N N N Y Normal - 
42 32 F N N N N 12 N N N N N N N N N N N N N Normal - 
43 33 F N N N N 12 N N N N N N N N N N N N N Normal - 
44 39 F N N N N 11 N N N N N N N N N N N N N Normal - 
45 37 F N N N N 10 N N N N N N N N N N N N N Normal - 
46 35 F N N N N 12 N N N N N N N N N N N N N Normal - 
47 33 F N N N N 13 Y N N N N N N N N N N N N Normal - 
48 32 F N N N N 9 Y N N N N N N N N N N N N Normal - 
         CHEST X-RAY FINDINGS HRCT FINDINGS   
ID Age Sex Dyspnea Cough Hemoptysis Pleurisy Duration Nephritis 
XPleural 
Effusion 
XReticular 
Opacities 
XAtelec 
tasis 
XConso 
lidation 
CT Pleural 
Effusion 
CT Thickened 
Pleura 
CT Interstitial 
Thickening 
CT Bronchi 
ectasis 
CT Parenchymal 
Bands 
CT Ground 
Glass 
Opacities 
CT Consoli 
dation 
CT Lympha- 
denopathy 
PFT Sputum 
49 31 F N N N N 10 N N N N N N N N N N N N N Normal - 
50 38 F N N N N 11 N N N N N N N N N N N N N Normal - 
 
 
KEY WORDS 
 F- Female 
 M- Male 
 Y- Yes 
 N- No 
 +- Positive 
 (-)  Negative 
